2025年美国临床肿瘤学会泌尿生殖系统癌症研讨会（ASCO-GU）将于当地时间2025年2月13日-2月15日在美国旧金山盛大召开。
本文抢先速览全体大会（5篇）、口头报告（12篇）、快速口头报告（17篇）和海报（LBA报告1篇）专题的重磅研究标题、讲者及报告时间（北京时间）。
General Session-全体大会
摘要号：657
Title：Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.
标题：Nectin-4靶向抗体偶联药物SHR-A2102治疗晚期或转移性尿路上皮癌患者的I期研究
讲者：唐碧霞
单位：北京大学肿瘤医院
时间：2025/2/15，5:36
摘要号：17
Title：Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).
标题：在ENZA-p（ANZUP 1901）试验中，针对高危、转移性、去势抵抗性前列腺癌患者，比较[¹⁷⁷Lu]Lu-PSMA-617联合恩扎卢胺vs恩扎卢胺单药治疗患者的总生存期和生活质量。
讲者：Louise Emmett
单位：St Vincent's Hospital
时间：2025/2/14, 2:50
摘要号：16
Title：Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617
标题：在177Lu-PSMA-617的PSMAfore研究中，基线与治疗期间循环肿瘤DNA（ctDNA）比例与转移性去势抵抗性前列腺癌（mCRPC）患者临床结局的相关性。
讲者：Johann De Bono
单位：The Royal Marsden NHS Foundation Trust
时间：2025/2/14, 3:00
摘要号：15
Title：World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.
标题：WOLVERINE：基于X-MET合作组织的随机试验个体患者数据（IPD）的全球寡转移性前列腺癌（omPC）荟萃分析
讲者：Chad Tang
单位：The University of Texas MD Anderson Cancer Center
时间：2025/2/14, 7:30
摘要号：437
Title：Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
标题：评估循环肾损伤标志物-1（KIM-1）作为晚期肾细胞癌（aRCC）预后和预测生物标志物的价值：CheckMate 214试验的事后分析
讲者：Wenxin Xu
单位：Dana-Farber Cancer Institute
时间：2025/2/16, 2:15
Oral Abstract Session-口头报告专场
摘要号：665
Title：Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.
标题：HER2阳性肌层浸润性膀胱癌（MIBC）患者接受维迪西妥单抗联合围手术期特瑞普利单抗的新辅助治疗：来自II期RC48-C017试验的最新疗效和安全性结果
讲者：盛锡楠
单位：北京大学肿瘤医院
时间：2025/2/15, 0:57
摘要号：LBA18
Title：Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
标题：在III期TALAPRO-2试验中，未筛选的转移性去势抵抗性前列腺癌（mCRPC）患者接受他拉唑帕利（TALA）+恩扎卢胺（ENZA）作为一线治疗的最终总生存期（OS）
讲者：Neeraj Agarwal
单位：Huntsman Cancer Institute at the University of Utah
时间：2025/2/14, 0:42
摘要号：20
Title：Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).
标题：哪些转移性激素敏感性前列腺癌（mHSPC）患者从雄激素受体通路抑制剂（ARPIs）中获益更多？STOPCAP个体参与者数据（IPD）荟萃分析。
讲者：David Fisher
单位：MRC Clinical Trials Unit at UCL
时间：2025/2/14, 0:52
摘要号：308
Title：Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.
标题：前列腺癌放疗剂量反应的基因特征预测指标：PORTOS在III期试验中的验证
讲者：Shuang Zhao
单位：Department of Human Oncology, University of Wisconsin-Madison
时间：2025/2/14, 0:10
摘要号：309
Title：Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).
标题：高危前列腺癌（HR-PCa）中的根治性前列腺切除术（RP）与放射治疗（RT）：基于两项III期随机试验（RCTs）个体患者数据（IPD）的模拟随机对照比较
讲者：Soumyajit Roy
单位：Rush University Medical Center
时间：2025/2/14, 0:20
摘要号：438
Title：Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
标题：卡博替尼（C）联合纳武利尤单抗（N）和伊匹木单抗（I）治疗初治晚期肾细胞癌（aRCC）：COSMIC-313研究的最终结果
讲者：Laurence Albiges
单位：Institut Gustave Roussy, Université Paris Saclay
时间：2025/2/16, 0:15
摘要号：439
Title：Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
标题：纳武利尤单抗联合卡博替尼（N+C）对比舒尼替尼（S）治疗初治晚期肾细胞癌（aRCC）：CheckMate 9ER试验的最终随访结果。
讲者：Robert Motzer
单位：Memorial Sloan Kettering Cancer Center
时间：2025/2/16, 0:25
摘要号：440
Title：KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
标题：KEYMAKER-U03 Substudy 03B：帕博利珠单抗（pembro）与靶向治疗联合用于晚期透明细胞肾细胞癌（ccRCC）的研究
讲者：Laurence Albiges
单位：Gustave Roussy, Paris-Saclay University
时间：2025/2/16, 0:35
摘要号：618
Title：Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.
标题：前瞻性COTRIMS试验（科隆转移性精原细胞瘤腹膜后淋巴结清扫术试验）的最终结果
讲者：Axel Heidenreich
单位：Department of Urology, University Hospital of Cologne
时间：2025/2/16, 1:00
摘要号：658
Title：Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.
标题：纳武利尤单抗（NIVO）辅助疗法对比安慰剂（PBO）用于高危肌层浸润性尿路上皮癌（MIUC）：来自CheckMate 274研究的额外疗效结果，包括肌层浸润性膀胱癌（MIBC）患者的总生存期（OS）
讲者：Matthew Milowsky
单位：University of North Carolina School of Medicine
时间：2025/2/15, 0:15
摘要号：659
Title：Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
标题：来自NIAGARA研究的额外疗效和安全性结果，以及对病理完全缓解（pCR）对长期结局影响的探索性分析
讲者：Matthew Galsky
单位：Icahn School of Medicine at Mount Sinai
时间：2025/2/15, 0:25
摘要号：661
Title：Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.
标题：新辅助免疫治疗药物度伐利尤单抗（MEDI 4736）联合新辅助化疗（吉西他滨/顺铂或卡铂）在治疗可切除高危上尿路尿路上皮癌患者中的安全性和有效性
讲者：Nadine Houede
单位：Institut de Cancérologie du Gard, Oncology Department, Montpellier University
时间：2025/2/15, 0:47
Rapid Oral Abstract Session-快速口头报告专场
摘要号：443
Title：Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.
标题：仑伐替尼联合特瑞普利单抗作为一线治疗晚期延胡索酸水合酶缺乏型肾细胞癌的单中心、单臂、II期研究
讲者：孔文
单位：上海交通大学医学院附属仁济医院
时间：2025/2/16, 4:55
摘要号：LBA138
Title：Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.
标题：Mevrometostat (PF-06821497)联合恩扎卢胺治疗转移性去势抵抗性前列腺癌（mCRPC）患者的随机剂量扩展研究
讲者：Michael Schweizer
单位：Division of Medical Oncology, University of Washington
时间：2025/2/14, 9:25
摘要号：1
Title：EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.
标题：EPIC-A：局部晚期或转移性阴茎癌患者接受西米普利单抗联合标准化疗序贯西米普利单抗维持治疗的II期试验
讲者：Amit Bahl
单位：Bristol Haematology and Oncology Centre
时间：2025/2/16, 5:05
摘要号：21
Title：Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.
标题：经皮雌二醇（tE2）贴片作为雄激素剥夺疗法（ADT）：在转移性（M1）前列腺癌中联合雄激素受体通路抑制剂（ARPIs）的有效性和安全性——来自STAMPEDE试验平台的随机对照研究
讲者：Nicholas James
单位：Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust
时间：2025/2/14, 9:15
摘要号：22
Title：Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).
标题：在寡转移性激素抵抗性前列腺癌中，除标准全身治疗外增加转移灶导向治疗的随机II期试验（GROUQ-PCS 9）
讲者：Tamim Niazi
单位：McGill University
时间：2025/2/14, 9:20
摘要号：310
Title：Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.
标题：雄激素剥夺治疗后睾酮水平恢复对高危前列腺癌患者总生存期的影响：一项III期试验的长期数据
讲者：Abdenour Nabid
单位：Centre Hospitalier Universitaire de Sherbrooke
时间：2025/2/14, 9:00
摘要号：311
Title：Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial.
标题：肠道健康与前列腺癌：一种富含特定植物化学成分的食品胶囊联合或不联合益生菌/益生元混合物对症状及疾病进展的影响——一项随机、双盲、安慰剂对照试验
讲者：Robert Thomas
单位：Addenbrooke's Hospital
时间：2025/2/14, 9:05
摘要号：312
Title：A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial
标题：针对接受主动监测的前列腺癌男性患者的高omega-3、低omega-6饮食联合鱼油干预：CAPFISH-3随机临床试验
讲者：William Aronson
单位：VA Greater Los Angeles Healthcare System
时间：2025/2/14, 9:10
摘要号：441
Title：Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.
标题：经治的透明细胞肾细胞癌（ccRCC）患者接受Casdatifan单药治疗的疗效、安全性和多剂量亚组分析：来自I期开放标签研究ARC-20的数据
讲者：Toni Choueiri
单位：Dana-Farber Cancer Institute
时间：2025/2/16, 4:45
摘要号：442
Title：Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).
标题：肾细胞癌的组织学特征与预后中的种族差异：来自法国肾癌研究网络（UroCCR-191）的见解
讲者：Xiaofan Lu
单位：Institut de génétique, biologie moléculaire et cellulaire (IGBMC)
时间：2025/2/16, 4:50
摘要号：444
Title：Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).
标题：MET驱动的晚期乳头状肾细胞癌的最终总生存期和新ctDNA分析（CALYPSO研究）
讲者：Francesca Jackson-Spence
单位：Barts Cancer Centre
时间：2025/2/16, 5:00
摘要号：662
Title：A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
标题：LY3866288（LOXO-435），一种强效、高度异构体选择性FGFR3抑制剂（FGFR3i）在FGFR3改变的晚期实体瘤患者中的首次人体1期研究：FORAGER-1的初步结果
讲者：Gopa Iyer
单位：Department of Medicine, Memorial Sloan Kettering Cancer Center
时间：2025/2/15, 8:00
摘要号：663
Title：Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
标题：德曲妥珠单抗（Dato-DXd）在局部晚期/转移性尿路上皮癌中的应用：I期TROPION-PanTumor01研究的最新结果
讲者：Funda Meric-Bernstam
单位：The University of Texas MD Anderson Cancer Center
时间：2025/2/15, 8:05
摘要号：664
Title：EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
标题：EV-302：III期全球研究enfortumab vedotin联合帕博利珠单抗（EV+P）对比化疗治疗初治局部晚期或转移性尿路上皮癌（la/mUC）的更新分析
讲者：Thomas Powles
单位：St. Bartholomew's Hospital
时间：2025/2/15, 8:10
摘要号：666
Title：Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study
标题：年轻发病膀胱癌（YOUC）患者中的临床进展期尿路上皮膀胱癌（CAUBC）：一项基因组学研究
讲者：Alina Basnet
单位：Department of Hematology/Oncology, SUNY Upstate Medical University
时间：2025/2/15, 8:15
摘要号：667
Title：A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
标题：针对BCG无应答的非肌层浸润性膀胱癌患者的度伐利尤单抗联合膀胱内灌注吉西他滨和多西他赛的I/II期试验（HCRN GU16-243：ADAPT-BLADDER队列4）
讲者：Noah Hahn
单位：Johns Hopkins University School of Medicine
时间：2025/2/15, 8:20
摘要号：815
Title：A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
标题：肌肉浸润性膀胱癌新辅助化疗免疫治疗后的风险适应性治疗（RETAIN-2）的2期试验
讲者：Pooja Ghatalia
单位：Fox Chase Cancer Center
时间：2025/2/15, 8:25
Poster Session-海报专场
摘要号：LBA141
Title：Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
标题：在III期TALAPRO-2试验中，他拉唑帕利（TALA）+ 恩扎卢胺（ENZA）作为同源重组修复（HRR）缺陷型转移性去势抵抗性前列腺癌（mCRPC）患者的一线（1 L）治疗的最终总生存期（OS）
讲者：Karim Fizazi
单位：Institut Gustave Roussy
[1] https://meetings.asco.org/meetings/2025-asco-genitourinary-cancers-symposium/326/program-guide/scheduled-sessions
[2] https://meetings.asco.org/abstracts-presentations/search?query=*&sortBy=Relevancy&filters=%7B%22meetingTypeName%22:%5B%7B%22key%22:%22Genitourinary%20Cancers%20Symposium%22%7D%5D,%22meetingYear%22:%5B%7B%22key%22:%222025%22%7D%5D,%22mediaType%22:%5B%7B%22key%22:%22Abstracts%22%7D%5D%7D&intcmp=cc_ascoorg_gu_abstract-title_site_meeting-carousel_all__glob_010725_021025_carousel_viewnow_aware_image-text_abstract-titles
排版编辑：肿瘤资讯-明小丽
苏公网安备32059002004080号
